Localization in human interleukin 2 of the binding site to the a chain (p55) 
the binding component of the intermediate-affinity receptor (5) . The complex of p55 and p70, with additional components, corresponds to the high-affinity IL-2R (5, 6) .
The biological functions of each of these receptors have been determined by studying the effects of IL-2 binding to cells expressing natural receptor proteins or recombinant receptors. Binding of IL-2 to lymphoid cells expressing only p70 induces internalization of IL-2, expression of p55, and activation of lymphokine-activated killer (LAK) cells to an early effector phase of cytolytic activity (7) (8) (9) (10) . The interaction of'IL-2 with p55 alone apparently does not result in any biological response (11) , but binding to the high-affinity p55/p70 complex is essential for triggering a full proliferative response by T cells and for the late phase ofeffector LAK cell function (7) .
To analyze the interactions between IL-2 and its receptors, we have used oligonucleotide-directed mutagenesis to map sites in IL-2 that interact with each receptor chain (12) . We had previously determined that Asp-20 in the NH2 terminus of IL-2 controls binding to the intermediate-affinity IL-2R,3 chain (13) . These studies were extended to allow us to identify a cluster of specific amino acids that form the binding site in IL-2 for the low-affinity IL-2Ra subunit. Substitutions of these p55-specific residues created IL-2 analogs that interact only with p70; these analogs can help dissect the functions of the receptor components.
METHODS AND MATERUILS Preparation of IL-2 Analog Proteins. The procedures for site-specific mutagenesis and for expression of IL-2 analog proteins in Escherichia coli were described (12, 13) . Nucleotide sequence of the mutations was analyzed as described (12) . Crude extracts of E. coli cells expressing analogs were prepared as described (12) . Selected analogs were purified by immunoaffinity chromatography with a murine monoclonal antibody (5B1) that binds recombinant huIL-2 (14) .
Analysis of IL-2 Analog Proteins. Each analog was characterized for bioactivity on the IL-2-dependent murine T-cell line CTLL-2 as described (12, 13) . Competitive binding to the human high-affinity IL-2R was done at 370C as described (12) by using a subline of constitutively activated YT cells that express both IL-2Ra and IL-2Rj. Competitive binding to the human low-affinity p55 and the intermediate-affinity p70 receptors was determined as described (13) , except that a subline of YT-1 cells expressing =13,000 p70 molecules per cell was used. The YT-1 cells were obtained from T. Waldmann and J. Burton (National Institutes of Health). Competitive binding to the murine IL-2R complex was determined by using EL4J-3.4 cells, a subline of the murine thymoma EL4 cell line transfected with a plasmid expressing recombinant murine low-affinity p58 receptor, as well as the high-affinity receptor (15) . For direct binding studies, Scatchard analysis was done with IL-2 proteins radiolabeled with Na1251 by using Enzymobeads (Bio-Rad) or Iodo-Gen (Pierce) to specific activities of 50 ACi/lgg (1 Ci = 37 GBq).
RESULTS
In previous studies, we had characterized the biological activity and binding of a series of IL-2 analogs that included mutations of individual residues from over two-thirds of the IL-2 molecule (12, 13). In a preliminary analysis, none of the analogs with decreased biological activity seemed to be affected in binding to the IL-2Ra chain while still maintaining binding to the IL-2Rj chain. To determine the amino acid(s) Abbreviations: IL-2, interleukin 2; huIL-2, human IL-2; IL-2R, interleukin 2 receptor; IL-2Ra, interleukin 2 receptor a chain or p55 subunit; IL-2Rf, interleukin 2 receptor f3 chain or p70 subunit; LAK, lymphokine-activated killer cells; R38A, Arg-38 --Ala; F42A, Phe42 -* Ala. §To whom reprint requests should be addressed. 4636 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
that interacts with IL-2Ra, a secondary analysis was undertaken to test analogs that had retained bioactivity in the competitive binding assays (16) . In these studies, we concentrated on the region of amino acids 30-60 because reports (17) Another residue adjacent to Arg-38 was also analyzed for its contribution to the p55-binding site ( Table 1) . Substitution of Phe-42 with Ala (F42A) resulted in an analog (IL-2 F42A) identical to IL-2 R38A-i.e., significantly decreased ability to interact with p55, while retaining full binding to p70. Four additional substitutions at position 42 confirm that this residue is essential for p55 binding but dispensable for p70 binding. Both hydrophobic (Leu) and polar (Ser) residues could be tolerated at this position without any significant diminution in biological activity; however, a charged residue (Lys) drastically decreased the bioactivity (to 2%), whereas substitution of a second polar residue (Gln) resulted in a smaller decrease. Again, no correlation between bioactivity and binding to the high-affinity receptor was noted for the multiple substitutions at position 42.
Two other residues in the vicinity ofArg-38 and Phe-42 also appear to affect p55 binding but in a different manner. Substitution of the Lys at positions 35 or 43 with the nonconservative amino acid Glu produced analogs with characteristics similar to R38A and F42A analogs-i.e., complete loss of p55 binding but significant p70 binding (Table 1) . However, replacement of Lys-35 with Ala had no significant effect on binding to the IL-2Ra chain. There was also only a minimal effect upon binding to the high-affinity receptor even when Glu was substituted at these positions. Therefore, in contrast to residues 38 and 42, positions 35 and 43 may tolerate some side chains but not a negative charge.
The results described above were obtained with protein from crude extracts. To validate these results, two analogs were purified to homogeneity and reassayed ( Table 1 , Fig. 1 ). Comparison of the IC50 values of purified IL-2 R38A and IL-2 F42A
with wild-type IL-2 in each of the three competitive binding assays confirmed that both residues are essential forp55 binding (Fig. 1C) . With some preparations ofpurified IL-2 R38A, a very low amount of competitive binding to p55 could sometimes be detected (Table 1) . Both analogs exhibited 50-100%o competitive binding to p70 (Fig. 1B) and low but detectable binding to the p55/p70 complex (Fig. lA) . The specific activity of the purified analogs was -1-2 x 107 units per mg, not significantly different from wild-type IL-2 (Table 1) .
Direct binding studies were used to determine the affinity of IL-2 R38A for the IL-2R (Fig. 2, Similar results were obtained with 125I-labeled IL-2 F42A analog protein (Fig. 2, Table 2 ). Scatchard analysis revealed that this analog also bound to the /3-chain p70 with intermediate affinity (Kd = 1.9 nM, Fig. 2B ). On YT cells ( Fig. 2A) , in the presence of p55, binding to IL-2R was not altered (Kd = 1.5 nM). The increase in Bm., for the F42A analog on YT and YT-1 cells compared with wild-type IL-2 or the R38A analog was observed several times (data not shown); the significance of these data are unclear.
We examined the basis for discordance between the significant bioactivity of the IL-2 R38A and F42A analogs and their decreased binding to the high-affinity receptor. The possibility of species differences between the murine CTLL cells used for the bioassay and the human IL-2R subunits present in the competitive binding assays was considered. Competitive binding was determined (Fig. 3) by using the murine EL4J-3.4 cell line, a derivative of EL4 transfected with the recombinant 13,000
The Kd and B.. were determined from data shown in Fig. 2 .
*Determined from Fig. 2A .
tDetermined from Fig. 2B Fig. 1 , except that murine cell line ELAJ-3.4 was used; these cells express recombinant murine low-affinity IL-2R (p58) and 1000-3000 murine high-affinity IL-2Rs per cell (15 
DISCUSSION
Using site-specific mutagenesis, we have identified a cluster of four amino acids-Lys-35, Arg-38, Phe-42, and Lys-43-that form at least part of the binding site of IL-2 for its low-affinity receptor. IL-2 analog proteins containing substitutions of each of these residues were unaffected in binding to the p70 intermediate-affinity receptor but had dramatically reduced ability to compete for binding to the p55 low-affinity receptor. Direct Scatchard analysis confirmed that two of these analogs exhibited intermediate-affinity binding only, even on cells expressing both a and chains of the highaffinity receptor.
The location and position of these residues that interact with p55 are consistent with antibody epitope mapping as well as with structural studies on IL-2. Neutralizing antibodies to IL-2 have been shown to recognize epitopes located in two distinct regions, either the NH2-terminal 20 amino acids or an internal region composed of residues 30-60. Those antibodies that block binding of human IL-2 to the p55 subunit recognize epitopes in this internal region (17) , which confirms our results that the a chain-specific residues lie between Lys-35 and Lys-43. The three-dimensional structure determination by Brandhuber et al. (18) indicated that IL-2 is a globular protein composed of six a-helices, labeled A through F. All four a chain-specific residues are located in a cluster in the middle ofthe second or B helix. Most strikingly, three of the four residues-i.e., Lys-35, Arg-38, and Phe-42-are positioned such that their side chains would be exposed on the same face of the a-helix, as predicted by helical wheel analysis (Fig. 4) . Thus, the binding site of IL-2 for p55 appears to be a linear epitope composed of at least four residues held in an a-helical structure. Additional substitutions in this helix indicate that other residues may contribute to helical stability or have minor effects upon p55 binding (data not shown). p55-negative analogs also exhibit full bioactivity on human cells. Mouse IL-2 analog proteins with mutations in the fifth a-helix (the E helix) have been described that are also bioactive but unable to bind murine IL-2Ra; however, no residues in this helix were concluded to be important for biological activity (21) . It is interesting that, although the four residues identified here as important for interaction with the human p55 receptor are absolutely conserved in mouse IL-2 (22), mouse IL-2 still has very low biological activity on human cells (23) .
The discordance between binding and biological activity of these analogs has important implications for our understanding of IL-2 interactions with the IL-2R complex. Saito et al. (24) have proposed an affinity conversion model in which IL-2 binds first to p55 and the IL-2/pSS complex then interacts with p70 to form the high-affinity ternary complex; the large numbers of p55 molecules (in excess over the p70 molecules) should accelerate the high-affinity binding. The affinity conversion model would predict that an IL-2 analog unable to bind to p55 would have no or reduced biological activity. However, specific activities of both R38A and F42A are 50-100% of that of wild-type IL-2, confirming that binding to p55 is not a prerequisite event for bioactivity. On activated YT cells, the a chain probably does not alter affinity of the p chain or the a//3 complex for these particular IL-2 analogs because the Kd values of IL-2 R38A and F42A for p70 vs. pSS/p70 did not differ significantly ( Table 2) .
The molecular basis for the unexpected lack of correlation between bioactivity and high-affinity binding deserves further study. Preliminary results indicate that the interaction of IL-2 analogs with only the p chain induces cointernalization of the ternary complex of IL-2, the 8 chain, and the a chain (W. Kuziel, G.J., and W. C. Greene, unpublished work). These observations can explain how binding of IL-2 to the 1 chain alone is sufficient for induction of bioactivity on T cells. Our results also support a model in which at least some of the IL-2 receptor molecules exist in a preformed complex of a and P chains; such a complex has been detected by crosslinking on the surface of mouse T cells (15) .
